Search
(3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium
go.drugbank.com/drugs/DB02648ExperimentalIt is used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias. [PubChem]
GMK
go.drugbank.com/drugs/DB06661ExperimentalGMK vaccine (a ganglioside conjugate vaccine coupled to keyhole limpet hemocyanin and formulated with the adjuvant QS-21) for the potential treatment of melanoma
HY10275
go.drugbank.com/drugs/DB05079ExperimentalHY10275 is a novel compound specifically designed to modulate two key neurobiological mechanisms that interfere with the sleeping process. HY10275 is highly selective for histamine H1 and serotonin 5HT2a, two chemical receptors that are ...
Rozrolimupab
go.drugbank.com/drugs/DB05209InvestigationalRozrolimupab is a recombinant polyclonal antibody consisting of 25 different anti-Rhesus D (RhD) antibodies to replace existing anti-RhD hyperimmune immunoglobulins for the treatment of Idiopathic Thrombocytopenic Purpura (ITP) and the p...
Synonyms: Recombinant human antigen-specific polyclonal antibody (pAb) against RhD antigen expressed in Chinese hamster ovary cellsHuman umbilical cord blood mononuclear cell-conditioned medium
go.drugbank.com/drugs/DB15724ExperimentalThus, the media in which they are cultured is believed to also have therapeutic potential. … Transplantation with human umbilical cord blood mononuclear cells (HUCBC) has demonstrated promising results in various disease states.
Cefovecin
go.drugbank.com/drugs/DB11505ExperimentalVet approvedIt is used for the treatment of skin infections caused by Pasturella multocida in cats, and Staphylococcus intermedius/S. canis in dogs. … Cefovecin is a cephalosporin antibiotic used for the treatment of skin infections in cats and dogs.
Urelumab
go.drugbank.com/drugs/DB12077InvestigationalUrelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. … The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with